Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tangbi is a Traditional Chinese Medicine (TCM) herbal prescription developed for the treatment of diabetic distal symmetric polyneuropathy (DSPN). It is typically used as an adjunct to standard care, such as mecobalamin, to alleviate symptoms including numbness, pain, and sensory loss. The formula is based on TCM principles of syndrome differentiation, aiming to improve blood circulation and resolve Bi (blockage) syndromes associated with chronic hyperglycemia. It has been evaluated in clinical trials to assess its impact on Michigan Diabetic Neuropathy Score (MDNS) and nerve conduction velocity, demonstrating potential advantages in relieving symptoms and reducing the incidence of DSPN exacerbations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tangbi.